New Capital Positions ABS to Reach Key Clinical Milestones and Advance Its Immuno-Corrective Autoimmune Therapy Platform

HOUSTON, May 13, 2026 — Autoimmunity BioSolutions (ABS), a biotechnology company developing a personalized, genetically-guided immuno-corrective therapy designed to normalize elevated levels of soluble IL7 receptor (sIL7R), today announced the close of a $1M seed extension financing round, bringing total seed capital raised to $3.1 million. The round was anchored by lead investor Eos BioInnovation and a select group of family offices whose long-term investment orientation reflects strong conviction in ABS’s differentiated scientific platform and its potential to transform outcomes for the millions of autoimmune patients inadequately served by current therapies.

The round includes continued participation from existing investors EOS BioInnovation, Independent Capital and Elmstead Partners, reflecting strong ongoing confidence in the ABS platform. ABS also welcomes NewTech Investment Holdings to the round as a new family office investor. Their participation anchors the $1M seed extension.

“We are grateful for the continued support of our family office partners, whose participation in this seed extension reflects shared belief in the transformative potential of our platform,” said Eugene Williams, MBA, Chief Executive Officer, Autoimmunity BioSolutions. “With the participation of seasoned investors who understand the pace and promise of life sciences innovation, we are well-positioned to deploy this capital with purpose, completing important animal model work and patient bio-sample analyses in our lead indication of Rheumatoid Arthritis, building on the compelling scientific momentum already underway at ABS.”

Advancing a Genetically Targeted Approach to Autoimmune Disease

ABS’s scientific team has identified a highly prevalent SNP, estimated to be present in roughly 50% of the overall population, which causes a 2–3-fold increase in circulating sIL7R. Elevated sIL7R has been repeatedly shown in scientific evidence to contribute to greater disease severity, increased disease progression, and reduced response to standard-of-care therapies across multiple autoimmune indications, including rheumatoid arthritis (RA), lupus nephritis (LN), and type 1 diabetes (T1D).

About Autoimmunity BioSolutions (ABS)

Autoimmunity BioSolutions (ABS) is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or “correct” elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease. This therapy targets a genetically defined subpopulation of autoimmune disease patients marked by a highly prevalent genetic variant (SNP) that elevates the expression of sIL7R and is associated with greater severity of disease, increased progression of disease, and poor response to current treatments. This immuno-corrective approach of targeting sIL7R in a genetic population is highly differentiated from current standards of care that rely on immunosuppressive mechanisms and has broad potential to enhance response to standards of care in the refractory population with elevated sIL7R across numerous autoimmune diseases. For more information, visit www.abstherapeutics.com or follow us on LinkedIn.

For investor inquiries, please contact:

Jen Beachell
Chief Business Officer
[email protected]

For media inquiries, please contact:
Madelyn De Los Santos
Putnam Insights
[email protected]

SOURCE Autoimmunity BioSolutions

New company formation, startup scaling, and founder growth contributed to more than $7.51B in cumulative economic impact across Central Ohio

COLUMBUS, Ohio, May 13, 2026 — Despite a challenging 2025 venture capital environment, particularly for founders raising pre-seed and seed funding, Central Ohio startups continued to demonstrate resilience, momentum, and growth. While venture investment nationally became increasingly concentrated among a small number of companies and coastal ecosystems, Central Ohio companies still raised $348 million across 55 deals in 2025, reflecting the continued strength of the region’s innovation economy.

Against that backdrop, founders supported by Rev1 Ventures, the Midwest venture studio partnering with innovators in SaaS/AI, deep tech, and life sciences, generated $718 million in total economic impact in 2025, as Central Ohio startups continued advancing from early traction to scalable growth.

Rev1’s 2025 Impact Report highlights that momentum, with supported founders generating $174 million in revenue, contributing to $274 million in exits, and creating or retaining 841 jobs. Collectively, Rev1 client companies now employ more than 2,700 people – equivalent to a top-20 regional employer based on workforce size.

Since 2013, Rev1-supported founders have generated $7.51 billion in cumulative economic impact, reflecting both the continued formation of new venture-backed companies and the sustained growth of startups scaling into larger, more established businesses.

The organization also reported an exceptionally high client satisfaction score, highlighting the continued demand for Rev1’s venture development model and founder support programs.

“These results reflect the strength and resilience of founders building high-growth companies in Central Ohio during one of the most challenging venture markets in recent years,” said Tom Walker, CEO of Rev1 Ventures. “Even as early-stage capital became harder to access nationally, founders in our ecosystem continued gaining traction, generating revenue, creating jobs, and positioning themselves for long-term scale. That’s exactly what Rev1 was built to do – help high-potential startups move from early validation to becoming venture-ready growth companies.”

A major milestone in that long-term strategy was the 2025 launch of Rev1 at The Peninsula, the organization’s new founder-focused innovation hub designed to support the next generation of software and advanced technology startups. Developed in partnership with the City of Columbus and Downtown Columbus, Inc., the space positions Columbus as home to one of the nation’s largest city-supported innovation centers dedicated to high-growth technology companies.

Rev1 will further highlight its 2025 Impact Report and new innovation hub during its upcoming Customer to Capital Accelerator Community Celebration on Wednesday, May 20, from 5–6:30 p.m. The event will bring together founders, investors, mentors, and community leaders to celebrate the latest graduates of Rev1’s tech accelerator and showcase emerging startups building in Central Ohio.

To learn more about Rev1 Ventures and its founder-focused venture studio model, visit:
Rev1 Ventures.com

About Rev1 Ventures
Rev1 Ventures is where founders go to build. As a Midwest venture studio, Rev1 partners with innovators in Saas/AI, deep tech, and life sciences to turn bold ideas into scalable companies. From day one, Rev1 helps startups move faster and grow smarter by validating markets, gaining traction, and becoming venture ready. A catalyst for early-stage growth, Rev1 connects founders to the mentors, partners, and early customers that accelerate progress and position startups to attract investors. With hands-on support, a powerful network, and collaborative spaces designed for growth, Rev1 gives startups the foundation to build stronger and scale.

SOURCE Rev1 Ventures

After generating more than $50M in projected medical and pharmacy savings across two Fortune 100 employers, 9amHealth is expanding its AI-driven specialty care platform beyond cardiometabolic care to address the high-cost chronic conditions that account for up to 70% of employer spend.

SAN DIEGO, May 13, 2026 — 9amHealth, a leading virtual specialty care platform, today announced $26 million in Series B funding led by Define Ventures, with new participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures. 

Since its founding, 9amHealth has rapidly emerged as a leader in virtual cardiometabolic care, partnering with large enterprise employers and leading pharmaceutical organizations to support people living with obesity, diabetes, hypertension, and hyperlipidemia. Through its integrated care model, which combines clinical protocols, labs, medication management, and continuous care, the company has delivered significant pharmacy cost savings amid rising demand for GLP-1 therapies while improving engagement and clinical outcomes.

Building on this foundation, 9amHealth has already developed the clinical infrastructure, care delivery model, and technology platform needed to manage complex, high-cost chronic conditions at scale. The new funding will support continued growth as the company expands its platform to address additional high-cost, specialty-level chronic conditions, which collectively account for up to 70% of employer pharmacy spend.

These conditions often require ongoing specialty medications, repeat interventions, and coordinated care, which represents the largest and fastest-growing portion of employer healthcare spend.

“What makes this possible is our ability to combine specialized clinical care with AI-enabled clinical workflows and personalized member experiences that allow us to scale efficiently across complex chronic conditions,” said Frank Westermann, CEO and Co-Founder of 9amHealth. “We’ve already proven this model in cardiometabolic care, and are now extending to a much broader set of high-cost needs.”

The Series B round was led by Lynne O’Keefe, Founder and Managing Partner at Define Ventures, who will join the company’s Board of Directors.

“We’re proud to partner with 9amHealth at this pivotal stage,” said Lynne O’Keefe. “They’ve demonstrated strong clinical outcomes and cost savings in one of the fastest-growing categories in healthcare. Their platform has the potential to transform how employers manage their most expensive populations.”

About 9amHealth
9amHealth is an AI-enabled virtual specialty care platform focused on managing high-cost chronic conditions at scale. The company partners with employers, health plans, and pharmacy benefit managers to deliver comprehensive, cost-effective medical care for individuals living with obesity, diabetes, hypertension, and dyslipidemia. Members receive access to specialized clinicians, including endocrinologists, obesity medicine specialists, and clinical pharmacists, at-home lab testing, prescription medications, and lifestyle support.

9amHealth was founded in 2021 and is backed by leading healthcare investors like Define Ventures, SemperVirens VC, 7Wire Ventures, and The Cigna Group Ventures.

Learn more at www.join9am.com.

Download media assets here.

SOURCE 9amHealth

Targeted $50M. Raised $55M. Thirty Days. No Pitch Deck. No Placement Agent. Every Dollar Inbound.

DALLAS, May 13, 2026 — Champion Leadership Group today announced the final close of SaaS Fuel™ Fund I at $55 million, oversubscribed from its original $50 million target and completed in under 30 days without a road show, a placement agent, a pitch deck, or a single cold outreach. Every dollar came inbound — from exited SaaS founders and senior technology executives who had worked directly with the firm.

Fund I targets approximately 30 B2B SaaS and AI companies in the $1M–$5M ARR range — the most structurally neglected stage in SaaS investment, too large for friends-and-family capital and too small for institutional funds whose check sizes require dilutive ownership at this valuation. Each portfolio company receives capital plus the full SaaS Fuel™ operational infrastructure: the SaaS Fuel Operating System™, the firm’s proprietary infrastructure trained on 81,000 closed private-market transactions; a monthly podcast reaching 12,000 founders; an email community of 17,000 operators; and the Founder Flywheel™ network connecting portfolio founders with exited operators who serve as advisors, early customers, and follow-on investors. Initial checks range from $500k – $3M, with reserved capital for future rounds.

The fund’s economic structure is built on the same alignment philosophy. The fund charges no management fee — a deliberate departure from the industry-standard 2% that would otherwise draw $1.1 million annually from investor capital regardless of performance. Carry is 20%, but only after a 9% preferred return hurdle: every LP receives their capital back plus a 9% annual return before any carry is distributed. Managing Partner Jeff Mains committed $5 million of personal capital — nearly 10% of the fund — at identical terms to every LP. Same entry. Same hurdle. Same lock-up. No exceptions.

When inbound commitments exceeded the $50M target, Mains chose to expand modestly rather than turn away the founders and operators who had been closest to the work over the longest period of time.

“Every person who invested had watched us work,” said Mains. “The oversubscription was not a marketing outcome — it was a trust outcome. That distinction matters more than most people in venture are willing to admit.”

The firm currently serves 240 active founder clients through its accelerator program. A Fund II has not been announced; the firm is focused on full deployment of Fund I. Fund I is actively investing.

About Champion Leadership Group
Champion Leadership Group is a Dallas, Texas-based B2B SaaS and AI scale-up accelerator and investment firm. SaaS Fuel™ Fund I — $55 million, no management fee, 20% carry after a 9% preferred return hurdle, $5M GP commitment at identical LP terms — closed oversubscribed in under 30 days. The SaaS Fuel Operating System™ is trained on 81,000 closed private-market transactions. Jeff Mains: five companies built, four exits. 240 active founder clients. Fund I is actively investing.

Media Contact:
Alex Carter, Media Relations
Champion Leadership Group
469-640-8545
[email protected]

SOURCE Champion Leadership Group

New capital fuels product enhancements as leading biopharma adopt QuartzBio to eliminate operational inefficiencies and protect trial outcomes

BALTIMORE, May 13, 2026 — QuartzBio, a life science technology company delivering portfolio‑scale sample and biomarker intelligence for clinical‑stage biopharma, today announced a strategic growth investment and controlling interest from Eir Partners, a private equity firm focused on health tech and tech-enabled services. The move marks a significant milestone as QuartzBio expands its role as trusted infrastructure for biopharma organizations seeking greater operational control, data integrity, and efficiency across complex clinical trial portfolios.

Addressing a Growing Operational Bottleneck in Clinical Development
As clinical trial portfolios scale, sponsors are forced to manage biospecimens and biomarker data across disconnected vendors, systems, and spreadsheets. This fragmentation introduces operational blind spots—driving missing or unusable samples, manual consent and collection tracking, late discovery of data gaps, costly downstream rework, and trial delays.

QuartzBio was built to eliminate this friction. Its vendor‑agnostic, AI‑enabled platform unifies sample collection, chain of custody, consent status, metadata integrity, and biomarker results into a single ecosystem—delivering real‑time visibility and control across entire clinical portfolios.

Proven Impact Across Clinical Operations
QuartzBio is trusted by a growing customer base that includes multiple Top 10 pharmaceutical companies, delivering operational clarity across complex clinical programs. The platform helps teams identify and resolve issues early—before they become protocol deviations, data loss, or trial delays—while integrating seamlessly into existing workflows.

Customers report near‑complete visibility into sample collection, reducing monitoring effort by up to 98% and significantly cutting manual work through automated oversight and exception management—allowing teams to support significantly more studies without adding headcount. These efficiencies drive $250K–$350K in average savings per Phase II/III study, while protecting timelines and ensuring biomarker‑ready data at readout.

By embedding domain‑specific AI directly into clinical and translational workflows, QuartzBio enables R&D teams to move faster and with greater confidence—without increasing operational risk or administrative burden.

Focused Investment in Product and Scale
The investment from Eir Partners enables QuartzBio to accelerate enhancements across its platform and operating model, including:

• Expanded portfolio‑scale interoperability across CROs, labs, and clinical systems
   
• Deeper AI‑driven automation for workflow management, risk detection, and data completeness
   
• Enhanced analytics and benchmarking for multi-trial decision‑making
   
• Increased enterprise scalability, security, and global compliance
   
• Expanded customer support and implementation capacity to match growing adoption

“Modern clinical development generates unprecedented volumes of data, yet trial risk persists because that data is fragmented, delayed, or unreliable,” said Scott Marshall, Ph.D., CEO of QuartzBio. “This investment allows us to double down on delivering a scalable software platform that removes manual oversight, protects scientific integrity, and materially reduces trial cost and duration.”

Investor Perspective
“AI is fundamentally transforming clinical development, and sample and biomarker intelligence represents one of its highest-impact applications,” said Brett Carlson, Founder and Chief Executive Officer of Eir Partners. “QuartzBio has demonstrated both strong product‑market fit and tangible economic impact for sponsors managing complex portfolios. By embedding domain-specific AI directly into clinical and translational workflows, the company is well positioned to shape how next-generation trials are conducted.”

Terms of the transaction with Eir Partners were not disclosed. Bourne Partners served as an exclusive financial advisor to QuartzBio.

About QuartzBio
QuartzBio is a life science technology company delivering connected sample and biomarker intelligence for clinical-stage biopharma. Designed for modern, multi-trial portfolios, its vendor‑agnostic platform unifies sample operations and biomarker data into a single platform—powered by domain‑specific AI agents—to reduce operational risk, accelerate timelines, and enable scientifically defensible outcomes. For more information, please visit their website at www.quartzbio.com or LinkedIn page.

About Eir Partners
Eir Partners Capital is a Miami-based private equity company focused on healthcare technology and tech-enabled services. Founded in 2015, Eir has partnered with entrepreneurs and management teams to create scaled, strategically differentiated platforms across payer, provider, employer, and pharma technology sectors. The Firm’s hands-on approach combines operational insight with deep industry relationships to drive long-term value. Targeted stages of investment include growth equity through control buyouts and equity check sizes range from $40 – $150 million or larger with co-investments. For more information, please visit their website at www.eirpartners.com or LinkedIn page.

SOURCE QuartzBio

Partnering with leading pharmaceutical companies, BranchLab replaces fragmented, offline workflows with a unified, privacy-first AI platform—driving a nearly 70% increase in commercialization efficacy.

BOULDER, Colo., May 13, 2026 — BranchLab, an AI platform transforming how pharmaceutical companies commercialize therapies, today announced a $26 million Series A financing led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The round brings total funding to $35 million.

Pharma commercialization—spanning patient identification, audience segmentation, activation, and real-world measurement—has historically relied on fragmented vendors, delayed analytics, and manual workflows. The result is a system that is data-rich but operationally offline, limiting how quickly teams can learn, adapt, and drive impact.

BranchLab is changing that.

The company has built a unified AI platform that puts audience identification, activation, and optimization directly in the hands of pharma teams and their agencies—enabling them to act on high-intent patient and healthcare professional (HCP) audiences in near real time. Today, BranchLab is used by leading pharmaceutical companies and has delivered an average increase of nearly 70% in marketing efficacy across a diverse set of therapeutic areas.

“Pharma has long had access to rich data, but using it quickly—and responsibly—has been the challenge,” said Josh Walsh, CEO of BranchLab. “BranchLab solves this by turning privacy-safe, aggregated data into real-time insights that connect directly to activation. Teams can move faster, reach the right audiences more effectively, and drive better outcomes without relying on sensitive or individual-level information.”

At the core of the platform is a novel transformer-based architecture that enables models to train on health data within customer-controlled environments, while deploying only non-sensitive demographic and media-side signals. The new approach transforms commercialization workflows that used to take months and collapses them to minutes.

“The more we learned about BranchLab, the more we saw the possibility to transform the way patients learn about and get started on the right therapies,” said Carrie Williams, partner at McKesson Ventures. “Combining a deep understanding of the patient journey with a future-proofed approach to patient activation could enable an evolved patient therapy experience, one that seamlessly bridges privacy-first audience targeting with patient access, affordability and preference.”

FCA emphasized the underlying system shift: “Pharma has spent years investing in data and analytics, but much of it still lives outside of production systems,” said Andrew Bouldin, Managing Partner at FCA Venture Partners. “BranchLab’s approach to running models within regulated environments and connecting them directly to execution is a fundamental shift in how commercialization can work. We see this as a meaningful step toward making pharma’s data, and activation systems work together in real time.”

Sanofi Ventures highlighted the broader industry shift toward embedded, privacy-aware AI systems.

“Healthcare is entering a new era of responsible AI within regulated environments,” said Cris De Luca, Sanofi Ventures. “BranchLab has the potential to become a core commercial intelligence layer, putting this capability directly in the hands of pharma teams to connect therapies with patients across next‑generation digital environments.”

As the industry moves toward faster, more accountable, and privacy-first systems, BranchLab is positioning itself as the infrastructure layer for how therapies are brought to market in the AI era.

With the new funding, BranchLab will expand enterprise deployments, deepen integrations across the healthcare and media ecosystem, and continue building the unified AI platform for pharma commercialization.

About BranchLab
BranchLab is transforming healthcare commercialization with AI-native technology that helps leading healthcare organizations and their agencies connect patients, providers, and caregivers to life-improving therapies and resources. Built for the evolving privacy landscape, BranchLab improves commercialization performance without relying on individual-level health information. By modernizing the industry’s technical infrastructure, BranchLab helps organizations operate more efficiently and responsibly, while enabling a healthier system for everyone.

To learn more, visit www.branchlab.com.

CONTACT:
BranchLab Media Team
[email protected]

SOURCE BranchLab Inc

The latest financing marks a new phase of scale as Oishii grows production, expands retail access, and advances its operations across the United States and Japan

JERSEY CITY, N.J., May 13, 2026 — Oishii, the company behind the world’s largest indoor vertical strawberry farm, today announced the first closing of $150 million in Series C financing led by SPARX Asset Management Co., Ltd., with participation from Nomura Real Estate Development Co., Ltd., MISUMI Group Inc., Mizuho Bank Ltd., and others. The financing reflects confidence in Oishii’s indoor Smart Farm™ model—which integrates robotics, automation, and advanced technology with centuries-old Japanese farming techniques—as the company increases production, advances farm operations, and broadens retail access to its pesticide-free, Non-GMO strawberries, which are grown year-round and harvested at peak ripeness.

While the vertical farming sector has cooled in recent years, Oishii has continued to gain momentum through a more focused approach to scale, using robotics and automation, broader consumer access, and continued technology innovation to differentiate itself within the category. Oishii has expanded its distribution across 18 states, launched in Toronto as its first international retail market, introduced new retail formats and product offerings, and is now advancing its R&D capabilities in Japan through the development of its first-of-its-kind Open Innovation Center in Tokyo.

Robotics and automation have become central to Oishii’s approach to scaling strawberry production with greater consistency, precision, and quality control. Following the acquisition of Tortuga AgTech in 2025, the company expanded those capabilities with additional harvesting robotics and engineering expertise. Earlier this year, Oishii also announced a strategic partnership with MISUMI Group Inc., a global supplier of manufacturing and automation components, to support its growing automation and manufacturing needs across the U.S. and Japan.

“Since our Series A investment in 2019, we have continuously supported Oishii Farm’s growth. It is truly inspiring to see the vision we shared at that time steadily becoming a reality, as the company advances seamlessly from research and development to proof of concept and commercialization,” said Shuhei Abe, President & CEO of SPARX Asset Management Co., Ltd. “One of the company’s key strengths lies in its exceptional execution capability, which has enabled rapid technological advancement. As Oishii Farm enters a new phase with the establishment of its Open Innovation Center in Japan, we look forward to continuing to support its growth.”

Oishii has also expanded beyond its original ultra-premium positioning into a more flexible retail business with broader consumer reach. Since launching the Omakase Berry at nearly $50 per tray in 2018, the company has added the Koyo Berry and Nikko Berry and introduced new pack sizes and retail formats designed for more everyday purchasing, with offerings today spanning $4.99 to $15. Its new Premium Preserves line also extends the brand beyond fresh berries into an elevated range of pantry staples.

The Nikko Berry, introduced in 2025, has also become a strong proof point for how Oishii applies demand, retail, and production insight to product innovation. Earlier this year, the company introduced its innovative stay-fresh top-seal packaging for the Nikko Berry, advancing a new approach to strawberry packaging focused on freshness, shelf life, and retail scalability while reducing plastic usage by 80% compared to traditional clamshell packaging.

Together, these milestones show Oishii entering a new phase of maturity and growth, scaling its differentiated model to expand production, reach more consumers, and help define the next phase of indoor vertical farming.

“When we chose strawberries, we knew we were selecting one of the hardest paths in indoor farming,” said Hiroki Koga, Co-Founder and CEO of Oishii. “They require precision at every stage, from pollination and harvesting to freshness and shelf life, and there were moments along the way where solving one challenge revealed the next one underneath it. This funding marks a new phase for Oishii as we scale what we’ve built, with deeper confidence in the decisions we’ve made and the role we can play in bringing high-quality produce to more people.”

With the first closing of Series C financing, Oishii plans to increase production capacity, advance robotics integration, expand farm infrastructure, and develop new product formats within its Smart Farm model, while continuing to invest in R&D and innovation capabilities across the United States and Japan.

Oishii has raised a total of $370M since its founding in 2016.

About Oishii
Oishii (which means “delicious” in Japanese) is the innovative company behind the world’s largest indoor vertical Smart Farm™. On a mission to transform the agriculture industry through the power of smart farming, Oishii harmoniously marries nature with state-of-the-art technology to create the ideal elements—rain, air, heat, light, nourishment and natural bee pollination—for growing in-season produce all year round. Oishii’s beloved Omakase, Koyo and Nikko Berries are grown in pesticide-free smart farms in the U.S. and proudly bear the Non-GMO Project Verified seal. Founded in 2016, Oishii’s investors include SPARX Asset Management, NTT, Yaskawa, McWin Capital Partners and Resilience Reserve. Oishii was recognized as one of Fast Company’s “World’s Most Innovative Companies” in 2022. For more information, visit www.oishii.com.

SOURCE Oishii

Led by SignalFire and HubSpot Ventures, the round backs Vector’s vision for contact-level advertising and a new interface that lets marketers talk to their data

BOSTON, May 13, 2026 — Vector, the contact-level advertising platform for B2B marketers, today announced a $10M Series A, led by SignalFire and HubSpot Ventures.

The funding will accelerate Vector’s development of an AI ad automation platform built to multiply the impact of B2B marketers, not replace them. Alongside the raise, Vector is launching Vector MCP, the only interface that brings Vector’s unique ability to associate de-anonymized ad clickers with ad performance data into LLMs like Claude and ChatGPT. This allows marketers to query campaign performance and buyer activity in natural language instead of digging through dashboards.

“Every marketer we talk to is trying to do more with the same budget and prove it’s working. Vector gives them something that hasn’t existed before, the ability to target specific buyers based on real intent signals in real time. We see the opportunity to connect all the dots in a buyer’s journey and optimize marketing touch-points based on what is working,” said Adam Coccari, Managing Director at HubSpot Ventures. “We’re excited to partner with the team as they build essential infrastructure for our shared customers and beyond.”

Vector pioneered contact-level advertising, helping marketers target named buyers based on intent signals like website visits, ad clicks, and competitor research.

“The teams that win in B2B GTM will be the ones who capture the right signals early, before intent is obvious and before a competitor gets there first. Vector has built something new: contact-level advertising that transforms anonymous interest into actionable signals and named audiences,” said Varun Ramakrishnan, Principal at SignalFire. “SignalFire invested because we believe that’s foundational to how modern marketers will build pipeline.”

With this investment, the company is building toward a future where AI handles the repetitive work so marketers can focus on strategy and creative, the parts requiring human taste and judgment. Vector MCP is the first step, letting marketers ask plain-language questions about their campaigns and buyer activity, and get answers without switching between platforms or waiting on reports.

“The prevailing narrative right now is that AI will replace your marketing team. We think that’s wrong,” said Joshua Perk, co-founder and CEO of Vector. “The real opportunity is using AI to compound what good marketers already do. We’re not building a product that takes the marketer out of the loop. We’re building one that gives them better data, faster answers, and the ability to operate at a scale that wasn’t possible before.”

About Vector

Vector is the contact-level advertising platform built for B2B marketers. Vector enables demand gen and ABM teams to build ad audiences by name—targeting the exact buyers they care about, not just companies or vague firmographic filters. Leading B2B marketers use Vector to run more precise campaigns, reduce wasted ad spend, and prove the impact of their programs. Backed by SignalFire and HubSpot Ventures.

SOURCE Vector

BOSTON, May 12, 2026 — FINTRX, the leading private wealth intelligence platform for asset managers and other investment professionals, today released its inaugural quarterly Family Office Report, with trends and intelligence for the first quarter of 2026. The findings indicate that family offices continue to be led by first-generation entrepreneurs, with a strong and growing preference for direct investments, private equity and venture capital versus hedge funds and fund-of-funds.

In the first quarter of 2026, FINTRX added 119 family offices worldwide to its platform, which now totals 4,503 multi- and single-family offices globally. FINTRX added 75 new single- and 44 multi-family offices to its platform during the quarter, with North America accounting for 49, Europe and Asia/Oceania with 25 each, Africa/Middle East, 13, and Latin America, seven.  

Key findings of the Q1 report include:

• Newly added family offices show a clear preference for actively managed alternatives — including direct investments, private equity, real estate, and venture capital — with select exposure to long-only listed equities and fixed income strategies, and comparatively lower interest in hedge funds and fund-of-funds structures.
• Of the 119 new profiles added during the quarter, single-family offices (SFOs) account for 63%, while multi-family offices (MFOs) make up 52% of the total FINTRX family office database.
• Among the 75 SFOs added during the quarter, 57% are Entrepreneur-origin, driven by wealth created in financial services, real estate, energy, technology and related sectors, and 40% are Generational-origin, driven by real estate, agriculture and financial services.
• FINTRX added 1,904 family office contacts in the quarter, showing a modest uptick in female representation versus the broader database, while leadership roles remain concentrated among men.

“First-generation entrepreneurial families are not just creating more family offices — they are investing in ways that look more like an extension of their business-building experience,” said Patrick Galvin, research associate for FINTRX. “That often means a preference for direct deals, private equity and venture capital, and a more selective approach to commingled fund structures.”

Beyond firm profiles, the report examines the 1,900+ newly added family office contacts, benchmarking them against nearly 30,000 total family office contacts in the FINTRX platform. Managing director, partner and investment analyst rank among the most common titles, reflecting the lean, senior-heavy structures typical of family offices, while prior employment trends point to a strong pipeline from global banks, Big Four accounting firms and leading consulting firms into family office roles.

Methodology
Data in the FINTRX Family Office Report is sourced from the FINTRX private wealth intelligence platform, which tracks more than 4,500 family office profiles and nearly 30,000 contacts across the global wealth channel. Coverage spans single and multi-family offices across all geographies, wealth origins, and investment mandates. All figures reflect the state of the FINTRX database as of March 31, 2026.

To access the full report, visit: https://www.fintrx.com/hubfs/FINTRX%20Q1%202026%20Family%20Office%20Intelligence%20Report.pdf.

About FINTRX
FINTRX is the leading private wealth intelligence platform, offering the industry’s most expansive and up-to-date data on registered investment advisors, broker-dealers, wealth teams, family offices, endowments and foundations. Powered by industry-leading AI, FINTRX helps firms distribute funds, raise capital, recruit advisors, identify M&A targets and drive strategic growth. For more information, visit fintrx.com.

Media contacts
Newton Park PR
Margaret Kirch Cohen
[email protected]
+1 847-507-2229

Kathy Panagopoulos
[email protected]
+1 773-710-7433

SOURCE FINTRX